For how we live.
A randomised trial enrolled 3,259 underserved people referred for lung cancer screening. Adding free medication to standard advice did not raise quit rates; adding financial incentives roughly doubled them — to 8.8%.
The publicly funded E4512 trial found two years of crizotinib after surgery did not prolong disease-free survival against observation, with a hazard ratio of 1.08 and no safety upside.
The final analysis of Roche's phase 3 trial found the anti-TIGIT antibody did not significantly extend progression-free or overall survival when added to atezolizumab in 521 patients.
In the phase 3 SWOG/NRG S1914 trial, adding atezolizumab to stereotactic radiotherapy for high-risk, inoperable early lung cancer left 2-year survival at 82% in both groups and caused more serious side effects.
Diets rich in colourful fruit and vegetables track with less cancer, so supplement makers bottled beta-carotene. Two large trials in smokers found the pills raised lung cancer and death — the opposite of the hope.
A pooled study of 1.44 million adults links activity to lower risk of 13 cancers — but not all, and not melanoma. A 2025 randomised trial now shows exercise after colon cancer improves survival.
A Global Burden of Disease 2023 study counts 1,102,794 incident tracheal, bronchus and lung cancers in Asians aged 60 and over in 2023, with ageing populations set to sustain the burden even as rates fall.
In a phase 3 trial, tambotatug pelitecan extended median survival to 13.3 months versus 9.4 on standard chemotherapy — but the trial was open-label and run entirely in China.
New guidelines set how the program, launched in July 2025, screens people aged 50 to 70 with a 30 pack-year smoking history using two-yearly low-dose CT scans.
The federal program enrols nearly 140,000 responders and survivors, most certified for a 9/11-related illness. Cohort data show a heavy, still-growing burden — and hint the program itself lowers mortality.
Registries show a real but narrow signal: a few cancers, led by prostate and thyroid, run high in 9/11 responders, while overall cancer incidence sits at or below the rate expected.
A, B, C, D and I are not school marks. They encode how strong the evidence is, whether to screen at all — and in the US, whether insurance has to pay for it.
In an early-phase trial of 136 previously treated patients, daraxonrasib produced responses in 31–37% depending on dose — but 54% had a serious side effect, and this is a phase 1–2 study.
Two large randomised trials found low-dose CT screening cut lung-cancer deaths in heavy smokers. The eligibility rules are narrow, and the reason is written into the evidence.
Stage describes how far a cancer has spread at diagnosis. It is not the same as grade, it is set once, and it drives both prognosis and treatment more than almost any other number.
The final HARMONi-A analysis reports a 2.7-month gain in median overall survival — 16.8 versus 14.1 months — for the PD-1/VEGF bispecific added to chemotherapy in a China-only phase 3 trial.
Fine particulate exposure in seven Amazonian capitals was tied to about 5,472 circulatory and 2,621 respiratory deaths over six years. A separate analysis finds cardiac mortality rising with forest loss.
A comparison of FDA, EMA and ANVISA decisions from 2020 to 2024 finds Brazilian approvals arriving about a year later. A second study clocks the wait for public-system financing in years, not months.
Bizengri now covers NRG1-fusion cholangiocarcinoma, a mutation found in a fraction of a fraction of cases. The evidence is 19 patients, of whom about a third responded.
A colourless gas that seeps from soil into homes accounts for a large share of lung cancers in never-smokers. The evidence for testing is strong; the risk rises smoothly with concentration, with no clear safe level.
Emergency restrictions came into force on 13 December when the index passed 450. The more telling number is how many days the city has now spent in a category that was meant to be exceptional.